Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals

• Published in: Current obesity reports Vol. 13; no. 4; pp. 818 - 830
• Main Authors: Au, Kahei, Zheng, Ming-Hua, Lee, Wei-Jei, Ghanem, Omar M., Mahawar, Kamal, Shabbir, Asim, le Roux, Carel W., Targher, Giovanni, Byrne, Christopher D., Yilmaz, Yusuf, Valenti, Luca, Sebastiani, Giada, Treeprasertsuk, Sombat, Hui, Hannah Xiaoyan, Sakran, Nasser, Neto, Manoel Galvao, Kermansaravi, Mohammad, Kow, Lilian, Seki, Yosuke, Tham, Kwang Wei, Dang, Jerry, Cohen, Ricardo V., Stier, Christine, AlSabah, Salman, Oviedo, Rodolfo J., Chiappetta, Sonja, Parmar, Chetan, Yang, Wah
• Format: Journal Article
• Language: English
• Published: New York Springer US 01-12-2024
• Subjects: Behavioral Therapy; Cardiology; Diabetes; Endocrinology; Medicine; Medicine & Public Health; Metabolic Diseases; Review; Topical Collection on Obesity Treatment; THR-beta agonists; Obesity; Resmetirom; GLP-1; Fatty liver; Metabolic surgery; Bariatric surgery; MASH; Liver fibrosis; MASLD; Liver cirrhosis
• ISSN: 2162-4968; 2162-4968
• DOI: 10.1007/s13679-024-00582-z

Purpose of Review
The approval of resmetirom brings great hope to patients with metabolic dysfunction-associated steatohepatitis (MASH). The purpose of this review is to explore its impact on the global health environment. The implementation of multidisciplinary management MASH is proposed.
Recent Findings
Resmetirom has benefits in the treatment of MASH, and its safety and effectiveness have been studied. The adverse events (AEs) need to be noticed. To improve patient outcomes, a multimodal approach with medication such as resmetirom, combined with metabolic and bariatric surgery (MBS) and lifestyle interventions can be conducted.
Summary
MASH, a liver disease linked with obesity, is a challenging global healthcare burden compounded by the absence of any approved pharmacotherapy. The recent conditional approval by the Food and Drug Administration (FDA) in the United States of resmetirom, an oral, liver-directed, thyroid hormone receptor beta-selective agonist, marks a significant milestone, offering a treatment option for adults with non-cirrhotic MASH and who have moderate to advanced liver fibrosis. This narrative review discusses the efficacy and safety of resmetirom and its role in the therapeutic landscape of MASH treatment. Despite the promising hepatoprotective effect of resmetirom on histological liver endpoints, its use need further research, particularly regarding ethnic differences, effectiveness and cost-effectiveness, production scalability, social acceptance and accessibility. In addition, integrating resmetirom with other multidisciplinary therapeutic approaches, including lifestyle changes and MBS, might further improve clinical liver-related and cardiometabolic outcomes of individuals with MASH. This review highlights the importance of a comprehensive treatment strategy, supporting continued innovation and collaborative research to refine treatment guidelines and consensus for managing MASH, thereby improving clinical patient outcomes in the growing global epidemic of MASH. Studies done to date have been relatively short and ongoing, the course of the disease is highly variable, the conditions of various patients vary, and given this complex clinical phenotype, it may take many years of clinical trials to show long-term benefits.